EQL PHARMA AB (7JK) — Cash Flow Reinvestment Rate
EQL PHARMA AB (7JK) has a Cash Flow Reinvestment Rate of 0.88x as of December 2025, reinvesting €11.87 Million (capex €11.87 Million ) from operating cash flow of €13.44 Million. Explore 7JK capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
EQL PHARMA AB Cash Flow Reinvestment Rate (2022–2023)
Historical reinvestment intensity for EQL PHARMA AB across 2 annual periods. Also explore how large is EQL PHARMA AB's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for EQL PHARMA AB (2022–2023)
Year-by-year capital reinvestment analysis for EQL PHARMA AB. For live market cap and broader valuation context, see market value of EQL PHARMA AB.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.74x | €20.51 Million | €27.62 Million | €20.51 Million | ▲ +40.6% |
| 2022 | 0.53x | €22.09 Million | €41.83 Million | €22.09 Million | — |